Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Medicare will pay up to $137.53 per case in 2027 for BriefCase‑Triage

Radiology Business reported Medicare will pay a maximum of $137.53 per case in 2027 for BriefCase-Triage. Holland & Knight said hospitals will be eligible for NTAP reimbursement for use of Aidoc’s CARE Body CT Multi-Triage beginning Oct. 1, 2026, with supplemental payments continuing for three years.

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

By MarketScale Newsroom · AidocCmsMedicareNtap
Share
Listen to the audio brief

Key facts, context, and what it means.

AUDIO
0:00
Medicare will pay up to $137.53 per case in 2027 for BriefCase‑Triage

Key takeaways

01

Radiology Business reported Medicare will pay a maximum of $137.53 per case in 2027 for BriefCase-Triage.

02

Holland & Knight said CMS approved an NTAP designation for Aidoc’s CARE Body CT Multi-Triage, with hospitals eligible for NTAP reimbursement beginning Oct. 1, 2026, with supplemental payments continuing for three years.

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Radiology Business reported Medicare will pay a maximum of $137.53 per case in 2027 for BriefCase-Triage. The outlet described Aidoc’s CARE (Clinical AI Reasoning Engine) Multi-Triage CT Body tool as using AI to analyze CT images and flag potentially urgent findings such as appendicitis or a bowel obstruction.

The payment sits inside the New Technology Add-On Payment (NTAP) program. Holland & Knight reported CMS approved an NTAP designation for Aidoc’s CARE Body CT Multi-Triage tool on Aug. 13, 2026, calling it the first time the agency has granted NTAP designation for an AI-enabled diagnostic tool.

What CMS actually approved, and what it pays

NTAP is a supplemental inpatient payment intended to make early adoption of qualifying technologies less financially risky, per Holland & Knight. The program is structured around three criteria: the technology must be new, it must be costly enough that the standard payment is inadequate, and it must represent a substantial clinical improvement over existing options.

Under the approved methodology, the add-on payment is the lesser of 65% of the technology’s cost or 65% of the amount by which a case’s cost exceeds the standard Medicare Severity Diagnosis-Related Group (MS‑DRG) payment, according to Holland & Knight.

Radiology Business reported Medicare will pay a maximum of $137.53 per case in 2027 for BriefCase-Triage. The outlet also reported the American College of Radiology summarized the figure as representing about 65% of the average cost of the technology.

The tool’s scope is broad, so billing discipline becomes the gating factor

Aidoc’s CARE Body CT Multi‑Triage analyzes contrast and non-contrast CT imaging of the chest, abdomen, and pelvis, and is designed to help prioritize cases with time-sensitive findings, Holland & Knight reported. Radiology Business described example urgent findings the system flags, such as appendicitis or bowel obstruction.

The key operational point is that payment depends on reliably flagging and coding qualifying cases. Radiology Business reported that Medicare will use ICD‑10‑PCS procedure code XEZ5XKC to mark eligible add‑on cases that involve the AI product, a code described as computer-aided triage and notification for imaging abnormalities in CT of chest, abdomen, and pelvis (new technology group 12).

Holland & Knight said hospitals should confirm they meet eligibility rules and align billing practices with CMS requirements to stay compliant when adopting NTAP-designated technologies.

A narrow window with real dollars attached

Holland & Knight said that starting Oct. 1, 2026, hospitals can receive NTAP reimbursement for using Aidoc’s CARE Body CT Multi-Triage technology, with supplemental payments continuing for three years.

Compliance and governance work starts before go-live

Holland & Knight said health systems should review eligibility, billing practices and CMS requirements when adopting NTAP-designated technologies. The firm also said systems should ensure compliance with HIPAA and state laws governing the use of AI programs in healthcare settings.

Featured companies

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

MarketScale Newsroom
MarketScale NewsroomEditorial Team, MarketScale

The MarketScale Newsroom reports on the companies, technologies, and trends shaping 16 B2B industries. It turns primary sources and expert commentary into clear, useful coverage for the people doing the work.

B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

Blair Health raises CAD $4.24M to expand its LLM-guided specialty care workflows

Blair Health raises CAD $4.24M to expand its LLM-guided specialty care workflows

Blair Health raised CAD $4.24 million in a pre-seed round, according to Fierce Healthcare. It plans to expand protocol-driven virtual specialty care across Canada and the U.S.

  • 01Blair Health raised CAD $4.24 million in pre-seed funding.
  • 02Qualified Health positions its AI platform around safety and governance, including clinician oversight, auditability and traceability, according to Fierce Healthcare.

Sep 23, 2026

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

About the Expert

MarketScale Newsroom
MarketScale Newsroom

Editorial Team

MarketScale

The MarketScale Newsroom reports on the companies, technologies, and trends shaping 16 B2B industries. It turns primary sources and expert commentary into clear, useful coverage for the people doing the work.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512